<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.immunityageing.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Immunity &amp; Ageing - Latest Articles</title>
        <link>http://www.immunityageing.com</link>
        <description>The latest research articles published by Immunity &amp; Ageing</description>
        <dc:date>2009-06-12T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/6/1/9" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/6/1/8" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/6/1/7" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/6/1/6" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/6/1/5" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/6/1/4" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/6/1/3" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/6/1/2" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/6/1/1" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/5/1/16" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.immunityageing.com/content/6/1/9">
        <title>The immune system and the impact of zinc during aging</title>
        <description>The trace element zinc is essential for the immune system, and zinc deficiency affects multiple aspects of innate and adaptive immunity. There are remarkable parallels in the immunological changes during aging and zinc deficiency, including a reduction in the activity of the thymus and thymic hormones, a shift of the T helper cell balance toward T helper type 2 cells, decreased response to vaccination, and impaired functions of innate immune cells. Many studies confirm a decline of zinc levels with age. Most of these studies do not classify the majority of elderly as zinc deficient, but even marginal zinc deprivation can affect immune function. Consequently, oral zinc supplementation demonstrates the potential to improve immunity and efficiently downregulates chronic inflammatory responses in the elderly. These data indicate that a wide prevalence of marginal zinc deficiency in elderly people may contribute to immunosenescence.</description>
        <link>http://www.immunityageing.com/content/6/1/9</link>
                <dc:creator>Hajo Haase</dc:creator>
                <dc:creator>Lothar Rink</dc:creator>
                <dc:source>Immunity &amp; Ageing 2009, 6:9</dc:source>
        <dc:date>2009-06-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-6-9</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2009-06-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/6/1/8">
        <title>Age-related changes in arthritis susceptibility and severity 
in a murine model of rheumatoid arthritis</title>
        <description>Background:
Rheumatoid arthritis (RA) most often begins in females in the fourth-fifth decade of their life, suggesting that the aging of the immune system (immunosenescence) has a major role in this disease. Therefore, in the present study, we sought to investigate the effect of age on arthritis susceptibility in BALB/c mice using the proteoglycan (PG)-induced arthritis (PGIA) model of RA.
Results:
We have found that young, 1-month-old female BALB/c mice are resistant to the induction of PGIA, but with aging they become susceptible. PG-induced T cell responses decline with age, whereas there is a shift toward Th1 cytokines. An age-dependent decrease in T cell number is associated with an increased ratio of the memory phenotype, and lower CD28 expression. Antigen-presenting cells shifted from macrophages and myeloid dendritic cells in young mice toward B cells in older mice. The regulatory/activated T cell ratio decreases in older mice after PG injections indicating impaired regulation of the immune response.
Conclusion:
We conclude that immunosenescence could alter arthritis susceptibility in a very complex manner including both adaptive and innate immunities, and it cannot be determined by a single trait. Cumulative alterations in immunoregulatory functions closely resemble human disease, which makes this systemic autoimmune arthritis model of RA even more valuable.</description>
        <link>http://www.immunityageing.com/content/6/1/8</link>
                <dc:creator>Oktavia Tarjanyi</dc:creator>
                <dc:creator>Ferenc Boldizsar</dc:creator>
                <dc:creator>Peter Nemeth</dc:creator>
                <dc:creator>Katalin Mikecz</dc:creator>
                <dc:creator>Tibor Glant</dc:creator>
                <dc:source>Immunity &amp; Ageing 2009, 6:8</dc:source>
        <dc:date>2009-06-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-6-8</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2009-06-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/6/1/7">
        <title>Adverse environmental conditions influence age-related innate immune responsiveness</title>
        <description>Background-The innate immune system plays an important role in the recognition and induction of protective responses against infectious pathogens, whilst there is increasing evidence for a role in mediating chronic inflammatory diseases at older age. Despite indications that environmental conditions can influence the senescence process of the adaptive immune system, it is not known whether the same holds true for the innate immune system. Therefore we studied whether age-related innate immune responses are similar or differ between populations living under very diverse environmental conditions.Methods-We compared cross-sectional age-related changes in ex vivo innate cytokine responses in a population living under affluent conditions in the Netherlands (age 20&#8211;68 years old, n = 304) and a population living under adverse environmental conditions in Ghana (age 23&#8211;95 years old, n = 562).Results-We found a significant decrease in LPS-induced Interleukin (IL)-10 and Tumor Necrosis Factor (TNF) production with age in the Dutch population. In Ghana a similar age-related decline in IL-10 responses to LPS, as well as to zymosan, or LPS plus zymosan, was observed. TNF production, however, did not show an age-associated decline, but increased significantly with age in response to co-stimulation with LPS and zymosan.Conclusion-We conclude that the decline in innate cytokine responses is an intrinsic ageing phenomenon, while pathogen exposure and/or selective survival drive pro-inflammatory responses under adverse living conditions.</description>
        <link>http://www.immunityageing.com/content/6/1/7</link>
                <dc:creator>Linda May</dc:creator>
                <dc:creator>Anita van den Biggelaar</dc:creator>
                <dc:creator>David van Bodegom</dc:creator>
                <dc:creator>Hans Meij</dc:creator>
                <dc:creator>Anton de Craen</dc:creator>
                <dc:creator>Joseph Amankwa</dc:creator>
                <dc:creator>Marijke Frolich</dc:creator>
                <dc:creator>Maris Kuningas</dc:creator>
                <dc:creator>Rudi Westendorp</dc:creator>
                <dc:source>Immunity &amp; Ageing 2009, 6:7</dc:source>
        <dc:date>2009-05-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-6-7</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2009-05-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/6/1/6">
        <title>Mung Bean nuclease mapping of RNAs 3&apos; end</title>
        <description>A method is described that allows an accurate mapping of 3&apos; ends of RNAs. In this method a labeled DNA probe, containing the presumed 3&apos; end of the RNA under analysis is allowed to anneals to the RNA itself. Mung-bean nuclease is then used to digest single strands of both RNA and DNA. Electrophoretic fractionation of &quot;protected&quot; undigested, labeled DNA is than performed using a sequence reaction of a known DNA as length marker. This procedure was applied to the analysis of both a polyA RNA (Interleukin 10 mRNA) and non polyA RNAs (sea urchin 18S and 26S rRNAs). This method might be potentially relevant for the evaluation of the role of posttrascriptional control of IL-10 in the pathogenesis of the immune and inflammatory mediated diseases associated to ageing. This might allow to develop new strategies to approach to the diagnosis and therapy of age related diseases.</description>
        <link>http://www.immunityageing.com/content/6/1/6</link>
                <dc:creator>Daniele Bellavia</dc:creator>
                <dc:creator>Giorgia Sisino</dc:creator>
                <dc:creator>Giorgio Papadopoulos</dc:creator>
                <dc:creator>Giusi Forte</dc:creator>
                <dc:creator>Rainer Barbieri</dc:creator>
                <dc:source>Immunity &amp; Ageing 2009, 6:6</dc:source>
        <dc:date>2009-05-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-6-6</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2009-05-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/6/1/5">
        <title>Modulation of immunity in young-adult and aged squirrel, Funambulus pennanti by melatonin and p-chlorophenylalanine</title>
        <description>Background:
Our interest was to find out whether pineal gland and their by melatonin act as modulator of immunosenescence. Parachlorophenylalanine (PCPA) &#8211; a &#946; adrenergic blocker, is known to perform chemical pinealectomy (Px) by suppressing indirectly the substrate 5-hydroxytryptamine (5-HT) for melatonin synthesis and thereby melatonin itself. The role of PCPA, alone and in combination with melatonin was recorded in immunomodulation and free radical load in spleen of young adult and aged seasonal breeder Indian palm squirrel Funambulus pennanti.
Results:
Aged squirrel presented reduced immune parameters (i.e. total leukocyte count (TLC), Lymphocytes Count (LC), % stimulation ratio of splenocytes (% SR) against T cell mitogen concanavalin A (Con A), delayed type hypersensitivity (DTH) to oxazolone) when compared to young adult group. Melatonin administration (25 &#956;g/100 g body mass/day) significantly increased the immune parameters in aged more than the young adult squirrel while PCPA administration (4.5 mg/100 g body mass/day) reduced all the immune parameters more significantly in young than aged. Combination of PCPA and melatonin significantly increased the immune parameters to the normal control level of both the age groups. TBARS level was significantly high in aged than the young group. PCPA treatment increased TBARS level of young and aged squirrels both while melatonin treatment decreased it even than the controls. Nighttime peripheral melatonin level was low in control aged group than the young group. Melatonin injection at evening hours significantly increased the peripheral level of nighttime melatonin, while combined injection of PCPA and melatonin brought it to control level in both aged and young adult squirrels.
Conclusion:
PCPA suppressed immune status more in aged than in adult by reducing melatonin level as it did chemical Px. Melatonin level decreased in control aged squirrels and so there was a decrease in immune parameters with a concomitant increase in free radical load of spleen. Decreased immune status can be restored following melatonin injection which decreased free radical load of spleen and suggest that immune organs of aged squirrels were sensitive to melatonin. Increased free radical load and decreased peripheral melatonin could be one of the reasons of immunosenescence.</description>
        <link>http://www.immunityageing.com/content/6/1/5</link>
                <dc:creator>Seema Rai</dc:creator>
                <dc:creator>Chandana Haldar</dc:creator>
                <dc:creator>Rajesh Singh</dc:creator>
                <dc:source>Immunity &amp; Ageing 2009, 6:5</dc:source>
        <dc:date>2009-04-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-6-5</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2009-04-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/6/1/4">
        <title>Molecular Ageing in Progeroid Syndromes: Hutchinson-Gilford Progeria Syndrome as a model</title>
        <description>Hutchinson-Gilford progeria syndrome (HGPS) is a rare premature aging disorder that belongs to a group of conditions called laminopathies which affect nuclear lamins. Mutations in two genes, LMNA and ZMPSTE24, have been found in patients with HGPS. The p.G608G LMNA mutation is the most commonly reported mutation. The aim of this work was to compile a comprehensive literature review of the clinical features and genetic mutations and mechanisms of this syndrome as a contribution to health care workers. This review shows the necessity of a more detailed clinical identification of Hutchinson-Gilford progeria syndrome and the need for more studies on the pharmacologic and pharmacogenomic approach to this syndrome.</description>
        <link>http://www.immunityageing.com/content/6/1/4</link>
                <dc:creator>Henrique Coutinho</dc:creator>
                <dc:creator>Vivyanne Falcao-Silva</dc:creator>
                <dc:creator>Raphael Nobrega</dc:creator>
                <dc:creator>Gregorio Goncalves</dc:creator>
                <dc:source>Immunity &amp; Ageing 2009, 6:4</dc:source>
        <dc:date>2009-04-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-6-4</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2009-04-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/6/1/3">
        <title>Ageing exacerbates damage of systemic and salivary neutrophils from patients presenting Candida-related denture stomatitis </title>
        <description>Background:
Ageing leads to a decline in the function of the immune system, increasing the body&apos;s susceptibility to infections through the impairment of T-cells, macrophages, neutrophils and dendritic cells Denture stomatitis is a primary oral disease affecting elderly denture wearers. The major etiologic factor involved in this pathology is the infection by Candida albicans, an opportunistic pathogen that causes local and disseminated diseases in immunosuppressed humans. Neutrophils play a critical role in the immune response against C. albicans and are continually present in the salivary fluid and in the blood. The aim of this study was to determine ageing-related changes in salivary and blood neutrophils and their potential implications in Candida-related denture stomatitis.
Results:
Our results showed a lower number of neutrophils in the saliva from patients presenting Candida-related denture stomatitis in comparison to their matched controls. Furthermore, fewer neutrophils were isolated from the saliva of aged control individuals in comparison to matched younger subjects. CXCR1, CD62L and CD11b expression were significantly greater on systemic neutrophils from younger control individuals. Elderly individuals showed more apoptotic salivary neutrophils and lower GM-CSF levels than younger ones, regardless of the occurrence of Candida infection. On the other hand, CXCL-8 concentrations were higher in the saliva from elderly individuals. Besides, TNF-&#945; was detected at elevated levels in the saliva from infected elderly subjects. Salivary neutrophils from elderly and young patients presented impaired phagocytic activity against C. albicans. However, just systemic neutrophils from elderly showed decreased phagocytosis when compared to the younger ones, regardless of the occurrence of infection. In addition, neutrophils from aged individuals and young patients presented low fungicidal activity.
Conclusion:
The data suggests that the Candida related-denture stomatitis is associated to neutrophils function deficiency, and ageing drastically appears to alter important characteristics of such cells, facilitating the establishment of this infection.</description>
        <link>http://www.immunityageing.com/content/6/1/3</link>
                <dc:creator>Thais Gasparoto</dc:creator>
                <dc:creator>Narciso Vieira</dc:creator>
                <dc:creator>Vinicius Porto</dc:creator>
                <dc:creator>Ana Campanelli</dc:creator>
                <dc:creator>Vanessa Lara</dc:creator>
                <dc:source>Immunity &amp; Ageing 2009, 6:3</dc:source>
        <dc:date>2009-03-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-6-3</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2009-03-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/6/1/2">
        <title>Phenotype of apoptotic lymphocytes in children with Down syndrome</title>
        <description>Background:
Down syndrome (DS) is the most common and best-known chromosomal disorder and is associated with several other pathologic conditions including immunodeficiency which makes a significant contribution to morbidity and mortality. Various immunological theories and observations to explain the predisposition of individuals with DS to various infections have been published, one of which is increased apoptotic cells.AimThe aim of this study was to identify the effect of apoptosis on both types of cells of specific immune response (T and B lymphocytes) in children with DS using Annexin V staining of phosphatidyserine (PS) as a specific marker of early apoptosis.Subjects and methodsThe study included 17 children with karyotypically ascertained DS (7 males and 10 females). Their ages ranged from 4 months to 14 years with mean age of 5.7 &#177; 4.35 years. Seventeen age and sex matched healthy children were included in the study as controls. Patients or controls with infections were excluded from the study. Complete blood picture, immunophenotyping, analysis of apoptosis using Annexin V was done at National cancer Institute to all children included in this study.
Results:
Although CBC, differential count, relative and absolute number of CD3+ and CD16+ did not show significant differences between DS children and control group, the relative and the absolute size of apoptotic CD3+ T lymphocytes, and the relative size of apoptotic CD19+ B lymphocytes were significantly higher in DS children than in controls. On the other hand, no significant difference was detected as regards the absolute size of CD19+ B lymphocytes in DS children and in controls
Conclusion:
our finding of increased early apoptotic cells (especially T cells) in DS children may emphasize the fact that the function of cells- and not their number- is main mechanism responsible for the impairment of the immune system in DS children and may further add to the known fact that cellular immunity is more severely affected than humoral immunity in these children. Further studies on apoptotic cellular phenotype in larger number of DS are needed</description>
        <link>http://www.immunityageing.com/content/6/1/2</link>
                <dc:creator>Solaf Elsayed</dc:creator>
                <dc:creator>Ghada Elsayed</dc:creator>
                <dc:source>Immunity &amp; Ageing 2009, 6:2</dc:source>
        <dc:date>2009-03-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-6-2</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2009-03-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/6/1/1">
        <title>Alterations of T cell activation signalling and cytokine production by postmenopausal estrogen levels</title>
        <description>Background:
Immunosenescence is an age-associated disorder occurring primarily in T cell compartments, including altered subset composition, functions, and activation. In women, evidence implicates diminished estrogen in the postmenopausal period as a contributing factor to diminished T cell responsiveness. Since hypoestrogenism is present in postmenopausal women, our objective focused on whether T cell activation, defined as signalling molecule expressions and activation, and function, identified as IL-2 production, were affected by low estrogen.
Methods:
Using Jurkat 6.1 T cells, consequences of 4 pg/ml (corresponding to postmenopausal levels) or 40 pg/ml (premenopausal levels) of estradiol (E2) were analyzed on signalling proteins, CD3-zeta, JAK2, and JAK3, determined by Western immunoblotting. These consequences were correlated with corresponding gene expressions, quantified by real time-polymerase chain reaction. Tyrosine phosphorylation of CD3-zeta was defined by immunoprecipitation and western immunoblotting following activation by T cell receptor (TcR) cross-linking. CD3-zeta expression and modulation was also confirmed in T cells from pre- and postmenopausal women. To assess functional consequences, IL-2 production, induced by PMA and ionomycin, was determined using enzyme-linked immunosorbent spot assay (ELISpot).
Results:
At 40 pg/ml E2, the level of signalling protein CD3-zeta was elevated 1.57-fold, compared with cells exposed to 4 pg/ml E2. The CD3-zeta proteins also exhibited altered levels of activation-induced phosphorylation in the presence of 40 pg/ml E2 versus 4 pg/ml: 23 kD phosphorylated form increased 2.64-fold and the 21 kD form was elevated 2.95-fold. Examination of kinases associated with activation signalling also demonstrated that, in the presence of 40 pg/ml E2, JAK2 protein expression was increased 1.64-fold (p &lt; 0.001) and JAK3 enhanced 1.79-fold (p &lt; 0.001) compared to 4 pg/ml. mRNA levels for CD3-zeta, JAK2, and JAK3 were significantly increased following exposure to 40 pg/ml E2 (2.39, 2.01, and 2.21 fold, respectively) versus 4 pg/ml. These findings were confirmed in vivo, since T cells from postmenopausal women exhibited 7.2-fold diminished CD3-zeta expression, compared to pre-menopausal controls and this expression was elevated 3.8-fold by addition of 40 pg/ml E2. Functionally, Jurkat cells exposed to 40 pg/ml E2 and activated exhibited significantly elevated numbers of IL-2 producing colonies compared to 4 pg/ml (75.3 &#177; 2.2 versus 55.7 &#177; 2.1 colonies, p &lt; 0.0001).
Conclusion:
Jurkat T cells exposed to 4 pg/ml E2 expressed significantly diminished activation signalling proteins, correlating with reduced IL-2 production. Lower signalling protein levels appear to result from decreased CD3-zeta, JAK2, and JAK3 gene expressions. These findings may provide a molecular basis for immunosenescence associated with the postmenopausal state.</description>
        <link>http://www.immunityageing.com/content/6/1/1</link>
                <dc:creator>Lowell Ku</dc:creator>
                <dc:creator>Cicek Gercel-Taylor</dc:creator>
                <dc:creator>Steven Nakajima</dc:creator>
                <dc:creator>Douglas Taylor</dc:creator>
                <dc:source>Immunity &amp; Ageing 2009, 6:1</dc:source>
        <dc:date>2009-03-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-6-1</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2009-03-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/5/1/16">
        <title>The management of cancer in the elderly: 
targeted therapies in oncology

</title>
        <description>Cancer is universally considered a disease of ageing. Today the management of elderly cancer patients poses many specific problems and it should be revisited in the light of the most recent advances in both diagnosis and treatment of human malignancies. In particular, the potential use of novel therapeutic options, based on therapeutic agents raised against molecular targets (the so called targeted therapy), appears to be promising in this clinical settings especially in view of the limited side-effects. The mainstays of cancer treatment during the twentieth century were surgery, radiation and chemotherapy. However, surgery is not curative in metastatic disease, radiation and chemotherapy are limited by side effects because they can&apos;t discriminate between healthy and cancerous cells. When key molecular changes responsible for malignant transformation were identified (e.g. growth factors and their receptors), it was hoped that new targeted agents, by inhibiting cancer-specific pathways, would spare normal cells and thereby offer improved safety benefits and a higher therapeutic index over standard chemotherapeutics. The most common targeted therapies used in clinical practice, i.e. monoclonal antibodies and small molecules, are described.</description>
        <link>http://www.immunityageing.com/content/5/1/16</link>
                <dc:creator>Biagio Agostara</dc:creator>
                <dc:creator>Giuseppe Carruba</dc:creator>
                <dc:creator>Antonella Usset</dc:creator>
                <dc:source>Immunity &amp; Ageing 2008, 5:16</dc:source>
        <dc:date>2008-12-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-5-16</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>16</prism:startingPage>
        <prism:publicationDate>2008-12-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
